Meliglix 25 Mg

Sitagliptin Hydrochloride, the active ingredient in Meliglix 25 Mg, is a Dipeptidyl peptidase-4 (DPP-4) inhibitor presented as a 25 mg tablet for oral use. It treats type 2 diabetes mellitus in adult patients by improving glycaemic control when combined with diet and exercise.

GNH USA supplies Meliglix 25 Mg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Meliglix (sitagliptin) is used within the antidiabetic drug class to manage blood glucose levels in type 2 diabetes.

- Type 2 diabetes mellitus: lowers HbA1c and fasting plasma glucose when added to diet and exercise. - Monotherapy in type 2 diabetes: provides glucose‑dependent insulin secretion without causing hypoglycaemia. - Combination therapy with metformin: enhances overall glycaemic control in patients inadequately controlled on metformin alone.

Common Side Effects: - Nasopharyngitis: mild inflammation of the nasal passages and throat. - Headache: transient mild to moderate head pain. - Upper respiratory tract infection: symptoms such as cough and congestion. - Nausea: occasional stomach upset. - Dizziness: brief episodes of light‑headedness.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe allergic reactions: including anaphylaxis, Stevens‑Johnson syndrome, or angioedema. - Severe joint pain: unexplained arthralgia that may be disabling. - Bullous pemphigoid: rare skin blistering disorder. - Hepatic injury: abnormal liver function tests or hepatitis.

Before initiating therapy, consider the following safety measures.

- Renal impairment: assess kidney function and adjust dose if necessary. - Hepatic impairment: use with caution in patients with liver disease. - Pancreatitis risk: discontinue if persistent severe abdominal pain occurs. - Hypersensitivity: stop treatment if signs of severe allergic reaction develop. - Pregnancy and breastfeeding: safety not established; avoid unless benefits outweigh risks. - Store at ambient temperature: keep below 25 °C, protect from moisture and keep in original packaging.

Sitagliptin may interact with other medicines; monitor accordingly.

Major Interactions (Avoid): - Concomitant insulin: increased risk of hypoglycaemia; dose adjustments required. - Sulfonylureas: may potentiate hypoglycaemic episodes.

Moderate Interactions (Monitor Closely): - Rifampin: reduces sitagliptin exposure, may diminish efficacy. - Digoxin: may increase digoxin serum concentrations. - Warfarin: potential alteration of INR, monitor coagulation parameters. - NSAIDs: may affect renal function, especially in patients with pre‑existing kidney disease.